The Food and Drug Administration (FDA) has certified a new Covid-19 antibody drug for people with high-risk health problems or allergies who can’t get protection from vaccination. The antibody-drug is authorised for long-term protection against the Covid-19 virus rather than short-term treatment.
People who can benefit from the antibody drug are cancer patients, organ transplant recipients and patients taking immune-suppressing drugs for diseases like rheumatoid arthritis. Health experts say that approximately 2 to 3 per cent of the population of the US is into that group.
- DPIIT Teams Up With Startup Policy Forum
- Rural Poverty Slips Below 5% for FY24
- Capital Infra Trust InvIT IPO Preview: Latest capital Infra GMP, Lot, Price & Key Dates
- Smartworks Leases a New Office Space in Gurugram
- Indian Railway Finance Shares Surge 3% on Signing an MoU with REMC
The FDA and other health officials have highlighted that antibody drugs are not a replacement for vaccines, the most effective, long-lasting and protection again coronavirus. Antibody drugs are hard to manufacture and cost over $1,000 per dose compared with regular vaccines, usually under $30 per dose.
